February 2019

Linnaeus Therapeutics Awarded $2,000,000 Phase 2 SBIR

By |2019-03-19T00:38:19+00:00February 21st, 2019|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 2 Small Business Innovation Research (“SBIR”) Award by the National Cancer Institute (“NCI”) of the National Institute for Health (“NIH”).

September 2018

Linnaeus Therapeutics Appoints Tina Garyantes, Ph.D., to Senior Vice President of Research and Development

By |2019-03-12T17:54:25+00:00September 1st, 2018|

Linnaeus Therapeutics Appoints Tina Garyantes, Ph.D., to Senior Vice President of Research and Development Haddonfield NJ, September 1, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced the appointment of Tina Garyantes, Ph.D., [...]

August 2018

Linnaeus Therapeutics Closes $4.4 Million Series A Financing

By |2019-03-14T13:44:01+00:00August 27th, 2018|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $4.4 million series A financing. Kairos Ventures, of Beverly Hills, California, led the financing with significant participation from the University of Pennsylvania, Linnaeus CEO, Patrick Mooney, and Linnaeus SVP, R&D, Tina Garyantes.

January 2018

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Melanoma Data

By |2019-03-13T12:43:06+00:00January 26th, 2018|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that preclinical data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.

November 2016

Linnaeus Therapeutics Awarded $300,000 Phase 1 STTR

By |2019-03-14T13:44:38+00:00November 18th, 2016|

Linnaeus Therapeutics Awarded $300,000 Phase 1 STTR by National Cancer Institute Haddonfield NJ, March 16, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 1 Small Business [...]

April 2016

Linnaeus Cofounders Publish Paper on Skin Pigmentation

By |2019-03-14T13:45:09+00:00April 26th, 2016|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.